Session Time: 1:15pm-2:45pm
Location: Hall 3FG
Objective: Parkinson’s disease (PD), – chronic progressive disease of the brain from the degeneration of the nigrostriatal neurons in the basal ganglia and impaired function. The clinical picture of BP is not limited only to motor disorders (hypokinesia, rigidity, restless tremor and postural instability). For many people suffering from PD, fatigue is a feeling of physical fatigue, a decrease in motor activity, which leads to disruption of all types of daily activities, difficulty in motor rehabilitation.
Background: To study some aspects of neuropsychiatric disorders (fatigue, anxiety and sleep disturbance) in observed patients with PD.
Methods: 38 patients (24 women, 14 men) with a confirmed diagnosis of Parkinson’s disease, whose average age was 56.7 ± 6.3 years, duration of the disease – from 1 to 8.5 years were examined. For the purpose of a comparative evaluation of the positive effect of Neurox, patients were randomly assigned to 2 groups, comparable in age, stage and duration of the disease. Patients of the 1st (main group) (n = 22) in addition to antiparkinsonian therapy took the drug Neuroks according to the following scheme. A comparative evaluation of the effectiveness of the drug Neurox was carried out according to various criteria.
Results: With an active survey, 98% of patients in both groups complained of fatigue of varying severity. The average index of the PFS-16 scale was 59.7 ± 10.3 points in the main group and 60 ± 10 points in the control group before treatment. After treatment with Neurox, more than 75% of patients reported a decrease in fatigue severity by 11.2%, which was reflected in the test data (53.4 ± 10.5 points). As the comparative analysis of the PFS-16 fatigue scales showed, the indicators were more pronounced when answering questions about the limitation of daily activity (before treatment, 4.0 ± 1.2 points, after treatment – 3.3 ± 0.8 points) and decrease in physical activity (up to – 4.3 ± 1.0 points, after – 3.3 ± 0.7 points) : due to fatigue everything is done “much longer” (up to – 4.1 ± 1 , 3 points, after – 3,2 ± 0,7 points), “less volume” of work is performed (up to – 4,2 ± 0,8 points, after – 3,2 ± 0,8 points).
Conclusions: Thus, in the course of the study, reliable data were obtained that Neurox has a positive effect on the overall well-being of patients, which is manifested by a decrease in the number of complaints of general weakness, increased fatigue. This was also confirmed by a study on the fatigue scales PFS-16 (a decrease in the total score from 59.7 ± 10.3 to 53.4 ± 10.5).The positive effect of Neurox is confirmed by the improvement of brain bioelectrical activity. The obtained results testify to the positive effect of Neurox on such neuropsychic disorders as fatigue, sleep disturbance, anxiety in patients with BP and the possible use of this drug in the complex treatment of patients with PD, which will also improve their quality of life.
To cite this abstract in AMA style:S. Lukmonov, D. Tolibov. Neuropsychiatric disorders in observed patients with Parkinson’s disease [abstract]. Mov Disord. 2018; 33 (suppl 2). https://www.mdsabstracts.org/abstract/neuropsychiatric-disorders-in-observed-patients-with-parkinsons-disease/. Accessed November 29, 2023.
« Back to 2018 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/neuropsychiatric-disorders-in-observed-patients-with-parkinsons-disease/